Journal of Clinical Oncology, Vol 4, 685-696, Copyright © 1986 by American Society of Clinical Oncology

ARTICLES

Treatment of advanced colorectal and gastric adenocarcinomas with 5- fluorouracil and high-dose folinic acid

D Machover, E Goldschmidt, P Chollet, G Metzger, J Zittoun, J Marquet, JM Vandenbulcke, JL Misset, L Schwarzenberg and JB Fourtillan

We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma. In each treatment course, the patients received both 5-FU (340 to 400 mg/m2/d by intravenous (IV) infusion for a period of 15 minutes) and folinic acid (200 mg/m2/d by IV bolus) for 5 consecutive days, with a 21-day interval between courses. Eighty-six patients with colorectal carcinoma were evaluated. The combined complete and partial response rates were 39% for 54 patients who did not receive prior chemotherapy and 22% for 32 patients who had previously received chemotherapy. Four patients who were previously resistant to 5-FU attained objective responses. The median time to disease progression for the 28 responders was 10 months. The median survival time of responders was 19.5 months, and the probability of their being alive at 2 years was 40%. Of 27 patients with gastric adenocarcinoma, 13 (48%) responded to therapy. Their median time to disease progression was 5.5 months. The median survival time of responders was 11 months, and their probability of being alive at 15 months was 30%. Toxicity was within acceptable limits. Toxic effects included stomatitis, diarrhea, conjunctivitis, skin rash, and mild myeloid hypoplasia. In a separate study, plasma concentrations of L-folates greater than 10(-5) mol/L were achieved after a rapid single IV injection of 200 mg/m2 of folinic acid. Comparisons of our results with those reported in previous studies on 5-FU administered as a single agent suggest that, in advanced colorectal and gastric adenocarcinoma, folinic acid administered in high doses enhances the effectiveness of 5-FU administered concomitantly. Furthermore, some colorectal tumors that were previously resistant to 5-FU become sensitive to this drug. The survival of the patients who responded to therapy was markedly improved over that observed in reported series of untreated patients with advanced colorectal and gastric adenocarcinomas.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Machover, A. Ulusakarya, and E. Goldschmidt Modulation of FU With High-Dose Folinic Acid Is Effective for Treatment of Patients With Gastric Carcinoma J. Clin. Oncol., January 1, 2008; 26(1): 164 - 164. [Full Text] [PDF]

				O. Bouche, J. L. Raoul, F. Bonnetain, M. Giovannini, P. L. Etienne, G. Lledo, D. Arsene, J. F. Paitel, V. Guerin-Meyer, E. Mitry, et al. Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803 J. Clin. Oncol., November 1, 2004; 22(21): 4319 - 4328. [Abstract] [Full Text] [PDF]

				T. Andre, P. Colin, C. Louvet, E. Gamelin, O. Bouche, E. Achille, N. Colbert, C. Boaziz, P. Piedbois, N. Tubiana-Mathieu, et al. Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial J. Clin. Oncol., August 1, 2003; 21(15): 2896 - 2903. [Abstract] [Full Text] [PDF]

				C. Louvet, T. Andre, J.M. Tigaud, E. Gamelin, J.Y. Douillard, R. Brunet, E. Francois, J.H. Jacob, D. Levoir, A. Taamma, et al. Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients J. Clin. Oncol., December 1, 2002; 20(23): 4543 - 4548. [Abstract] [Full Text] [PDF]

				P. Ross, M. Nicolson, D. Cunningham, J. Valle, M. Seymour, P. Harper, T. Price, H. Anderson, T. Iveson, T. Hickish, et al. Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer J. Clin. Oncol., April 15, 2002; 20(8): 1996 - 2004. [Abstract] [Full Text] [PDF]

				M. Benchalal, E. Yahchouchy-Chouillard, S. Fouere, and A. Fingerhut Anaphylactic shock secondary to intravenous administration of folinic acid: a first report Ann. Onc., March 1, 2002; 13(3): 480 - 481. [Abstract] [Full Text] [PDF]

				E. Bajetta, R. Buzzoni, L. Mariani, E. Beretta, F. Bozzetti, G. Bordogna, E. Aitini, S. Fava, G. Schieppati, G. Pinotti, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group Ann. Onc., February 20, 2002; 13(2): 299 - 307. [Abstract] [Full Text] [PDF]

				G. Bocci, R. Danesi, A. Di Paolo, F. Innocenti, G. Allegrini, A. Falcone, A. Melosi, M. Battistoni, G. Barsanti, P. F. Conte, et al. Comparative Pharmacokinetic Analysis of 5-Fluorouracil and Its Major Metabolite 5-Fluoro-5,6-dihydrouracil after Conventional and Reduced Test Dose in Cancer Patients Clin. Cancer Res., August 1, 2000; 6(8): 3032 - 3037. [Abstract] [Full Text]

				S. Giacchetti, B. Perpoint, R. Zidani, N. Le Bail, R. Faggiuolo, C. Focan, P. Chollet, J. F. Llory, Y. Letourneau, B. Coudert, et al. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil-Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer J. Clin. Oncol., January 5, 2000; 18(1): 136 - 136. [Abstract] [Full Text] [PDF]

				Y. Tan, X. Sun, M. Xu, X. Tan, A. Sasson, B. Rashidi, Q. Han, X. Tan, X. Wang, Z. An, et al. Efficacy of Recombinant Methioninase in Combination with Cisplatin on Human Colon Tumors in Nude Mice Clin. Cancer Res., August 1, 1999; 5(8): 2157 - 2163. [Abstract] [Full Text] [PDF]

				W. Kern, J. Braess, B. Bottger, C. C. Kaufmann, W. Hiddemann, and E. Schleyer Oxaliplatin Pharmacokinetics during a Four-Hour Infusion Clin. Cancer Res., April 1, 1999; 5(4): 761 - 765. [Abstract] [Full Text] [PDF]

				M. Summerhayes, S. J Wanklyn, R. A Shakespeare, and J. Lovell Reduced pharmacy resource utilization associated with raltitrexed treatment of advanced colorectal cancer Journal of Oncology Pharmacy Practice, March 1, 1997; 3(1): 24 - 30. [Abstract] [PDF]

				E. Rakowsky, B. Klein, G. Marshak, and H. Lurie 5-fluorouracil and high dose folinic acid in symptomatic advanced colorectal carcinoma: importance of symptomatic relief Palliative Medicine, July 1, 1991; 5(3): 250 - 255. [Abstract] [PDF]

				A. I. Dreyfuss, J. R. Clark, J. E. Wright, C. M. Norris Jr., P. M. Busse, J. W. Lucarini, B. G. Fallon, D. Casey, J. W. Andersen, R. Klein, et al. Continuous Infusion High-Dose Leucovorin with 5-Fluorouracil and Cisplatin for Untreated Stage IV Carcinoma of the Head and Neck Ann Intern Med, February 1, 1990; 112(3): 167 - 172. [Abstract] [PDF]